CareDx Q3 Earnings Call Highlights Raised '26 Outlook & Testing Growth

Impact · against what's priced in

CareDx is a positive catalyst due to significant upward revisions in 2026 revenue and EBITDA guidance. The combination of stronger transplant demand and the integration of the specialty oncology business drives a fundamental shift in the company's immediate profitability outlook.

CDNA+0.70

No priced-in read yet

In context

The company raised its 2026 revenue guidance to $520M-$530M (up from $490M-$500M) and substantially increased adjusted EBITDA guidance to $90M-$100M from $66M-$78M.

Read from the article alone

• earnings▲3%
• revenue growth
• healthcare
• guidance
• CDNA
• diagnostics
• oncology
• profitability

Top 1 mover · tap to explore